Risedronate 150mg Once a Month in the Treatment of Postmenopausal Osteoporosis: 2 Year Efficacy and Safety Data

Michael R. McClung(Bone Health and Osteoporosis Foundation), Steven Boonen(KU Leuven), Christian Roux(Hôpital Pasteur), C. L. Benhamou(Inserm), Artur Racewicz, José Zanchetta(Universidad del Salvador), Z. Man(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rachelle Eusebio(Procter & Gamble (United States))
Journal of Clinical Densitometry
July 1, 2009
10.1016/j.jocd.2009.03.019
Cited by 0

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial
|The Lancet|2009|837
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508